Project Grant R21AI182698
Award Date
7/7/25
Completion Date
6/30/27
Dollars Obligated
$461K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $479,249 to Washington University to conduct research on the molecular mechanisms regulating neutrophil proinflammatory activity in sepsis. The research aims to understand how neutrophil A20 signaling contributes to organ damage in sepsis, utilizing biochemical, cell biological, and intravital imaging...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of a novel monocyte transcriptional state, termed "monocyte substate 1" (MS1), in the immunopathogenesis and patient heterogeneity of sepsis. The 5-year project will apply single-cell RNA...
The University of Rochester was awarded a $462,000 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate how the microbiome in healthy human blood differentially "primes" or trains neutrophils, leading to varied inflammatory responses during sepsis. The research aims to elucidate the mechanisms underlying this microbiome-mediated immune...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $721,728 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the Regents of the University of Michigan. The grant aims to investigate how persistent viral infections, such as human cytomegalovirus and Epstein-Barr virus, may worsen clinical outcomes and decrease response to immunomodulatory therapies in pediatric patients with sepsis. The research project will leverage...
This Project Grant award of $455,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to decrease sepsis mortality in the pediatric population. The key products and services to be delivered include: Developing an AI-guided early sepsis identification tool to enable timely diagnosis and treatment. Performing sepsis phenotyping and creating digital twin patient models to predict personalized treatment responses....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $684,206 to the University of Maryland, Baltimore to develop immunomodulatory nanoparticles (INPs) as a novel therapeutic approach to improve outcomes for patients with sepsis. The primary objectives are to: 1) evaluate the immunomodulatory properties of INPs to maximize therapeutic efficacy in a sepsis...
This $598,228 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to investigate the role of endoplasmic reticulum autophagy (ER-phagy) in the immune response during sepsis. The research team at the University of Illinois will use state-of-the-art methods to define the mechanisms by which ER-phagy regulates the NLRP3 inflammasome activation and cytokine release in macrophages, ultimately contributing to lung injury during...
This Project Grant award of $186,221 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop personalized sepsis therapeutics for pediatric patients. The key objectives are to: 1) Augment sepsis phenotypes using high-frequency physiologic data to identify additional subtypes and predict disease progression; 2) Retrospectively identify signs of bloodstream infection prior to traditional diagnostic signs...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $615,891 to conduct a multi-year study on sepsis pathobiology in sub-Saharan Africa (SSA). The primary awardee, The Trustees of Columbia University, will lead a team to validate the presence of distinct sepsis "endotypes" in Uganda that reflect host-pathogen features unique to the region. They will...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is supporting research to investigate the role of T cells in promoting post-acute memory deficits after COVID-19 infection in mice. The $107,995 award to The Washington University, which runs from July 2025 to June 2027, will fund a study to determine how pathogenic CD4+ T cells are recruited to the central nervous...